 Amid another soft performance for the benchmark equities index, rare-eye disease specialist Kala Pharmaceuticals NASDAQ: KALA lit up the overcast sky with a stunning triple-digit performance. Yesterday afternoon, the company announced that it received approval by the Food and Drug Administration FDA for its investigational new drug IND application centered on its flagship therapeutic candidate KPI-012. 